A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.

Bauer MS, Gruber S, Hausch A, Gomes PSFC, Milles LF, Nicolaus T, … Lipfert J
Proceedings of the National Academy of Sciences of the United States of America 2022 doi:10.1073/pnas.2114397119 PubMed
AFM force spectroscopy

Results

ObservableValueSource sentence
Unbinding force26 pNan initial (leftmost) peak typically at lower forces around 26 pN for the SARS-CoV-1 fusion construct and about twice as high forces for the SARS-CoV-2 fusion construct (around 57 pN; Fig. 2 A, Inset)
Unbinding force57 pNan initial (leftmost) peak typically at lower forces around 26 pN for the SARS-CoV-1 fusion construct and about twice as high forces for the SARS-CoV-2 fusion construct (around 57 pN; Fig. 2 A, Inset)
Unfolding force40 pNThis initial peak is followed by a trident-shaped, three-peak pattern at around 40 pN.
Contour length increment53 nmThe contour length increments of the first peaks (53 and 66 nm for the short and long linkers, respectively), are, however, larger than what is expected from interface opening only
Contour length increment66 nmThe contour length increments of the first peaks (53 and 66 nm for the short and long linkers, respectively), are, however, larger than what is expected from interface opening only
Rupture force1,500 pNThe final ClfA:Fgɣ rupture at >1,500 pN is not shown, for clarity.

Auto-extracted; verify against the paper before reuse.

Biological system

  • SARS-CoV-2 RBD:ACE2 tethered ligand fusion construct · protein
  • SARS-CoV-1 RBD:ACE2 tethered ligand fusion construct · protein
  • Human ACE2 (GLN18-SER740, C-terminal His-tag), soluble blocking agent · protein
  • ClfA:fibrinogen gamma peptide anchoring pair · protein

Data availability

Abstract

SignificanceIn the dynamic environment of the airways, where SARS-CoV-2 infections are initiated by binding to human host receptor ACE2, mechanical stability of the viral attachment is a crucial fitness advantage. Using single-molecule force spectroscopy techniques, we mimic the effect of coughing and sneezing, thereby testing the force stability of SARS-CoV-2 RBD:ACE2 interaction under physiological conditions. Our results reveal a higher force stability of SARS-CoV-2 binding to ACE2 compared to SARS-CoV-1, causing a possible fitness advantage. Our assay is sensitive to blocking agents preventing RBD:ACE2 bond formation. It will thus provide a powerful approach to investigate the modes of action of neutralizing antibodies and other agents designed to block RBD binding to ACE2 that are currently developed as potential COVID-19 therapeutics.